@article{90e30f10a9b3416b8f5244a82c321ee3,
title = "Cancer Hallmarks: Piecing the Puzzle Together",
author = "Alcolea, \{Maria P.\} and Direna Alonso-Curbelo and Chiara Ambrogio and Susan Bullman and Correia, \{Ana Lu{\'i}sa\} and Aur{\'e}lie Ernst and Halbrook, \{Christopher J.\} and Kelly, \{Gemma L.\} and Lund, \{Amanda W.\} and Quail, \{Daniela F.\} and Marcus Ruscetti and Efrat Shema and Stromnes, \{Ingunn M.\} and Tam, \{Wai Leong\}",
note = "C. Ambrogio reports research fees from Revolution Medicines, Aelin Therapeutics, Verastem, Roche, and Boehringer-Ingelheim. G.L. Kelly is an employee of WEHI, which receives milestone and royalty payments related to venetoclax; in addition, G.L. Kelly has received research funding from Servier. A.W. Lund reports consulting services for AGS Therapeutics, Inc. I.M. Stromnes reports personal fees from Immunogenesis and other support from Luminary Therapeutics outside the submitted work; in addition, I.M. Stromnes has a patent for Mesothelin TCR issued, licensed, and with royalties paid, a second patent for Mesothelin TCR issued, a patent for Chimeric costimulatory receptors issued and with royalties paid, a patent for Trex mouse model pending, and a patent for Mutant KRAS TCR issued, licensed, and with royalties paid. E. Shema reports personal fees from SEQLL outside the submitted work. S. Bullman reports personal fees from AstraZeneca and personal fees from Roche outside the submitted work; in addition, S. Bullman has a patent for PCT/US2018/042966 pending and a patent for F053-0188USP1/22-158-US-PSP pending. M. Ruscetti reports personal fees from Boehringer Ingelheim outside the submitted work. No disclosures were reported by the other authors.",
year = "2024",
month = apr,
day = "1",
doi = "10.1158/2159-8290.CD-24-0097",
language = "English",
volume = "14",
pages = "674--682",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "John Wiley and Sons Inc.",
number = "4",
}